Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in July 2015 on request of the Sponsor.
On 10 June 2003, orphan designation (EU/3/03/144) was granted by the European Commission to Barrier Therapeutics NV, Belgium, for liarozole for the treatment of congenital ichthyoses.
The sponsorship was transferred to Stiefel Laboratories (U.K.) Limited, United Kingdom, in June 2010.
Treatment of congenital ichthyoses
|Date of designation||
|Orphan designation status||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.